VTGN News and Press, VistaGen Therapeutics Inc. From 01/24/23

Small U.S. Phase 1 trial with newly optimized formulation to confirm favorable safety profile from three previous clinical trials and facilitate Phase 2B development of PH10 as a stand-alone treatment for major depressive disorder Vistagen (NASDAQ: VTGN) a late clinical-stage biopha...

VistaGen Therapeutics (NASDAQ: VTGN) , a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders, is preparing to launch a phase 1 trial of its novel ...

(NewsDirect) By Rachael Green, Benzinga In the race to create faster-acting, safer antidepressants, Vistagen (NASDAQ: VTGN) is starting the year strong as it gets ready to launch a Phase 1 Trial of its novel pherine nasal spray for Major Depressive Disorder (MDD). The trial, involving...

Robinhood Stocks That Can Be Bought For Pennies Whether you call them “ penny stocks ” or “cheap stocks,” there’s something exciting about some of the lowest-priced names in the stock market today. They come with plenty of risks, and brokers know this. D...

Penny Stocks Under $1: Worth The Risk Or Avoid Entirely? Are penny stocks worth it? The answer to that question depends on who you ask. In many cases, these higher-risk investments tend to scare away would-be traders and investors simply due to their volatility profile. The assumption is to t...

Vistagen (NASDAQ: VTGN) is a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders. The company today announced that the last patient has completed...

Topline results of the exploratory Phase 2 clinical study anticipated in Q1 2023 Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CN...

VistaGen Therapeutics (NASDAQ: VTGN) , a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders, has recently filed national applications at the U.S....

Vistagen’s recent patent filings in the U.S. and numerous additional countries mark the next step in the Company’s ongoing efforts to enhance potential commercial protection across its CNS pipeline in key pharmaceutical markets Vistagen (Nasdaq: VTGN), a late clinical-...

VistaGen Therapeutics will acquire Pherin Pharmaceuticals , which is focused on neuropsychiatric and neuroendocrine conditions. Deal terms call for VistaGen ( NASDAQ: VTGN ) to pay with 12.4M shares of its common stock as well as some cash. Pherin's latest stage asset is PH94B, ...